Global Hypertension Drugs Market 2016-2020

高血圧治療薬の世界市場2016-2020

◆タイトル:Global Hypertension Drugs Market 2016-2020
◆商品コード:IRTNTR9233
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年4月13日
◆ページ数:87
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、高血圧治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、パイプライン分析、高血圧治療薬の世界市場規模及び予測、種類別分析、薬剤種類別分析、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・パイプライン分析
・高血圧治療薬の世界市場:市場規模及び予測
・高血圧治療薬の世界市場:種類別分析
・高血圧治療薬の世界市場:薬剤種類別分析
・高血圧治療薬の世界市場:成長要因
・高血圧治療薬の世界市場:課題
・購買基準
・市場動向
・競争状況
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Hypertension Drugs
Hypertension, or high blood pressure (BP), develops when there is too much pressure against the inner walls of blood vessels. Depending on the pressure exerted, hypertension can be classified as:
• PAH
• Systemic hypertension (commonly referred to as hypertension)

PAH, high BP in the arteries that carry blood from the heart to the lungs, occurs when blood vessels narrow, making blood flow difficult. This creates pressure on the heart’s right ventricle, which increases in size and becomes weaker due to the excess load, leading to heart failure. The normal pulmonary arterial pressure at rest is 14 mmHg and increases from 25 mmHg to 30 mmHg.

Systemic hypertension occurs when blood vessels that supply oxygenated blood to the body become narrower, creating pressure on the right side of the heart. Hypertension can lead to damaged organs and illnesses such as renal failure (kidney failure), aneurysm, heart failure, stroke, or heart attack. Hypertension is classified into two types:
• Primary or essential hypertension: It is defined as high BP with no known cause, and includes around 90%-95% of all hypertension cases
• Secondary hypertension: It is high BP with a known direct cause, including kidney disease, tumors, or birth control pills, and includes 5%-10% of all hypertension cases

Technavio’s analysts forecast the global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hypertension drugs market for 201652020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent hypertension and pulmonary arterial hypertension (PAH).

The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC

Technavio’s report, Global Hypertension Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Actelion Ltd.
• AstraZeneca plc
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Company, Ltd.
• Novartis AG
• Sanofi SA

[Other prominent vendors]
• Actelion Pharmaceuticals
• Arena Pharmaceuticals
• Asahi Kasei
• Bayer HealthCare
• Bellerophon Therapeutics
• Bial
• CJ HealthCare
• Conatus Pharmaceuticals
• Daiichi Sankyo
• Deka Pharmaceuticals
• Dong-A ST
• Eiger BioPharmaceuticals
• Forest Laboratories
• Gilead Sciences
• HanAll BioPharma
• Hanmi Pharmaceutical
• Johnson & Johnson
• LG Life Sciences
• Lung Biotechnology
• Lupin Pharmaceuticals
• Mast Therapeutics
• Merck
• Northern Therapeutics
• Ono Pharmaceutical
• Pfizer
• PhaseBio
• Pluristem Therapeutics
• Quantum Genomics
• Radikal Therapeutics
• Reata Pharmaceuticals
• Serodus
• sigma-tau i.f.r
• SteadyMed Therapeutics
• Suda
• Sun Pharmaceutical Industries
• Symplmed Pharmaceuticals
• Takeda Pharmaceuticals
• United Therapeutics
• Valeant Pharmaceuticals
• XOMA
• Yuhan

[Market driver]
• Growing older population
• For a full, detailed list, view our report

[Market challenge]
• Patent expiries of major drugs
• For a full, detailed list, view our report

[Market trend]
• Increase in awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Cardiovascular drugs market
• Global pharmaceuticals market
• Global cardiovascular drugs market

PART 06: Overview: Hypertension
• Systemic hypertension
• PAH

PART 07: Epidemiology and economic burden
• Economic burden

PART 08: Pipeline portfolio

PART 09: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 10: Market segmentation by type
• Global systemic hypertension drugs market
• Global PAH drugs market

PART 11: Market segmentation by drug class
• Systemic hypertension
• PAH

PART 12: Geographical segmentation
• Global hypertension drugs market by geographical segmentation 2015-2020
• Hypertension drugs market in Americas
• Hypertension drugs market in EMEA
• Hypertension drugs market in APAC

PART 13: Market drivers
• Growing older population
• Rise in sedentary lifestyle
• High prevalence of chronic conditions
• Patient assistance programs

PART 14: Impact of drivers

PART 15: Market challenges
• Patent expiries of major drugs
• Adverse effects
• Poor patient compliance
• Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Increase in awareness
• Increased focus on combination therapies
• Intense competition among vendors
• Strategic alliances

PART 18: Vendor landscape
• Competitive scenario
• Market share 2015
• Novartis
• Daiichi Sankyo
• Actelion Pharmaceuticals
• Boehringer Ingelheim
• Sanofi
• AstraZeneca
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for drugs that treat hypertension
Exhibit 03: Patent expiries of major cardiovascular drugs
Exhibit 04: Global cardiovascular drugs market by generic and branded drugs sales 2015
Exhibit 05: Top 10 companies in global cardiovascular drugs market 2014
Exhibit 06: Pathophysiology of hypertension
Exhibit 07: Treatment algorithm for hypertension
Exhibit 08: Prevalence of PAH by cause
Exhibit 09: Projected prevalence of CVDs in US 2010-2030 (% of population)
Exhibit 10: Prevalence of hypertension in US population 2010-2030 (% of population)
Exhibit 11: Projected direct and indirect burden of hypertension in US 2010-2030 ($ billions)
Exhibit 12: Projected mortality trend for CVDs globally 2015 and 2030
Exhibit 13: Pipeline portfolio: Global systemic hypertension drugs
Exhibit 14: Pipeline portfolio: Global PAH drugs
Exhibit 15: Market share of global hypertension drugs in global pharmaceutical market 2015
Exhibit 16: Global hypertension drugs market 2015-2020 ($ billions)
Exhibit 17: Five forces analysis
Exhibit 18: Global hypertension drugs market segmentation by type 2015
Exhibit 19: Global systemic hypertension drugs market 2015-2020 ($ billions)
Exhibit 20: Global PAH drugs market 2015-2020 ($ billions)
Exhibit 21: Segmentation of global hypertension drugs market by drug class
Exhibit 22: Global systemic hypertension drugs market share by drug class 2015
Exhibit 23: Global PAH drugs market share by drug class 2015
Exhibit 24: Segmentation of global hypertension drugs market based on geography 2015
Exhibit 25: Hypertension drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 26: Percentage share of hypertension drugs market by geography 2015-2020
Exhibit 27: Hypertension drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Hypertension drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Hypertension drugs market in APAC 2015-2020 ($ billions)
Exhibit 30: Global hypertension drugs market: YoY growth rate and revenue based on geography 2015-2020
Exhibit 31: Population aged 60 years and over: World, developed, and developing regions ($ millions)
Exhibit 32: Impact of drivers
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Sales of major drugs in global hypertension drugs market 2014 ($ billions)
Exhibit 35: Novartis: YoY growth rate and revenue of Diovan 2012-2015 ($ billions)
Exhibit 36: Novartis: YoY growth rate and revenue of Exforge 2012-2015 ($ billions)
Exhibit 37: Novartis: Key takeaways
Exhibit 38: Daiichi Sankyo: YoY growth rate and revenue of Olmetec in Japan 2012-2014 ($ millions)
Exhibit 39: Daiichi Sankyo: YoY growth rate and revenue of Olmetec/Olmetec Plus in Europe 2012-2014 ($ millions)
Exhibit 40: Daiichi Sankyo: YoY growth rate and revenue of Rezaltas in Japan 2012-2014 ($ millions)
Exhibit 41: Daiichi Sankyo: YoY growth rate and revenue of Artist in Japan 2012-2014 ($ millions)
Exhibit 42: Daiichi Sankyo: YoY growth rate and revenue of Benicar/Benicar HCT in US 2012-2014 ($ millions)
Exhibit 43: Daiichi Sankyo: YoY growth rate and revenue of AZOR in US 2012-2014 ($ millions)
Exhibit 44: Daiichi Sankyo: YoY growth rate and revenue of TRIBENZOR in US 2012-2014 ($ millions)
Exhibit 45: Daiichi Sankyo: YoY growth rate and revenue of Sevikar in Europe 2012-2014 ($ millions)
Exhibit 46: Daiichi Sankyo: YoY growth rate and revenue of Sevikar HCT in Europe 2012-2014 ($ millions)
Exhibit 47: Daiichi Sankyo: Key takeaways
Exhibit 48: Actelion Pharmaceuticals: YoY growth rate and revenue of Tracleer 2011-2014 ($ billions)
Exhibit 49: Actelion Pharmaceuticals: YoY revenue of Opsumit 2013 and 2014 ($ millions)
Exhibit 50: Actelion Pharmaceuticals: YoY growth rate and revenue of Ventavis 2011-2014 ($ millions)
Exhibit 51: Actelion Pharmaceuticals: YoY growth rate and revenue of Veletri 2011-2014 ($ millions)
Exhibit 52: Actelion Pharmaceuticals: Key takeaways
Exhibit 53: Boehringer Ingelheim: YoY growth rate and revenue of Micardis 2012-2014 ($ millions)
Exhibit 54: Boehringer Ingelheim: Key takeaways
Exhibit 55: Sanofi: YoY growth rate and revenue of Aprovel 2012-2014 ($ millions)
Exhibit 56: Sanofi: YoY growth rate and revenue of Tritace 2012-2014 ($ millions)
Exhibit 57: Sanofi: YoY growth rate and revenue of Lasix 2012-2014 ($ millions)
Exhibit 58: Sanofi: Key takeaways
Exhibit 59: AstraZeneca: Business segmentation by revenue 2015
Exhibit 60: AstraZeneca: YoY growth rate and revenue of Seloken/Toprol 2013-2015 ($ millions)
Exhibit 61: AstraZeneca: YoY growth rate and revenue of Atacand 2013-2015 ($ millions)
Exhibit 62: AstraZeneca: YoY growth rate and revenue of Tenormin 2012-2014 ($ millions)
Exhibit 63: AstraZeneca: Key takeaways



【掲載企業】

Actelion Ltd., AstraZeneca plc, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Ltd., Novartis AG, Sanofi SA, Actelion Pharmaceuticals, Arena Pharmaceuticals, Asahi Kasei, Bayer HealthCare, Bellerophon Therapeutics, Bial, CJ HealthCare, Conatus Pharmaceuticals, Daiichi Sankyo, Deka Pharmaceuticals, Dong-A ST, Eiger BioPharmaceuticals, Forest Laboratories, Gilead Sciences, HanAll BioPharma, Hanmi Pharmaceutical, Johnson & Johnson, LG Life Sciences, Lung Biotechnology, Lupin Pharmaceuticals, Mast Therapeutics, Merck, Northern Therapeutics, Ono Pharmaceutical, Pfizer, PhaseBio, Pluristem Therapeutics, Quantum Genomics, Radikal Therapeutics, Reata Pharmaceuticals, Serodus, sigma-tau i.f.r, SteadyMed Therapeutics, Suda, Sun Pharmaceutical Industries, Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, Yuhan.

【資料のキーワード】

高血圧、高血圧薬、全身性高血圧、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[高血圧治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆